Lipopolyplex potentiates anti-tumor immunity of mRNA-based vaccination.

[1]  G. Hartmann,et al.  Enhanced Dendritic Cell Maturation by TNF-α or Cytidine-Phosphate-Guanosine DNA Drives T Cell Activation In Vitro and Therapeutic Anti-Tumor Immune Responses In Vivo1 , 2000, The Journal of Immunology.

[2]  C. Heirman,et al.  Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy. , 2012, Cancer research.

[3]  Z. Berneman,et al.  Clinical use of dendritic cells for cancer therapy. , 2014, The Lancet. Oncology.

[4]  A. Schambach,et al.  Lentiviral Protein Transfer Vectors Are an Efficient Vaccine Platform and Induce a Strong Antigen-Specific Cytotoxic T Cell Response , 2015, Journal of Virology.

[5]  Z. Modrušan,et al.  Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing , 2014, Nature.

[6]  C. van Broeckhoven,et al.  Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. , 2001, Blood.

[7]  K. Cibulskis,et al.  Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes , 2015, Nature Biotechnology.

[8]  B. Neyns,et al.  A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  H. Rammensee,et al.  Results of the First Phase I/II Clinical Vaccination Trial With Direct Injection of mRNA , 2008, Journal of immunotherapy.

[10]  Stefaan C De Smedt,et al.  Evading innate immunity in nonviral mRNA delivery: don't shoot the messenger. , 2016, Drug discovery today.

[11]  I. Melero,et al.  Therapeutic vaccines for cancer: an overview of clinical trials , 2014, Nature Reviews Clinical Oncology.

[12]  H. Rammensee,et al.  Genetic Vaccines and Therapy , 2006 .

[13]  R. Steinman,et al.  Dendritic cells and the control of immunity , 1998, Nature.

[14]  Klaus Ley,et al.  M1 and M2 Macrophages: The Chicken and the Egg of Immunity , 2014, Journal of Innate Immunity.

[15]  Youngjin Choi,et al.  Injectable, spontaneously assembling inorganic scaffolds modulate immune cells in vivo and increase vaccine efficacy , 2014, Nature Biotechnology.

[16]  F. Marincola,et al.  gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. , 2011, The New England journal of medicine.

[17]  Yuhua Wang,et al.  Systemic delivery of modified mRNA encoding herpes simplex virus 1 thymidine kinase for targeted cancer gene therapy. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[18]  M. Ferrari,et al.  Porous silicon microparticle potentiates anti-tumor immunity by enhancing cross-presentation and inducing type I interferon response. , 2015, Cell reports.

[19]  N. Restifo,et al.  B16 as a Mouse Model for Human Melanoma , 2000, Current protocols in immunology.

[20]  H. Harashima,et al.  Multifunctional Envelope-Type Nano Device: Evolution from Nonselective to Active Targeting System. , 2015, Bioconjugate chemistry.

[21]  B. Sullenger,et al.  From the RNA world to the clinic , 2016, Science.

[22]  J. Koenderink.  Q… , 2014, Les noms officiels des communes de Wallonie, de Bruxelles-Capitale et de la communaute germanophone.

[23]  C. Heirman,et al.  mRNA-based dendritic cell vaccines , 2015, Expert review of vaccines.

[24]  D. Kasper,et al.  A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design , 2011, Nature Medicine.

[25]  A. Thess,et al.  A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs , 2014, Therapeutic advances in vaccines.

[26]  T. Eberlein.  gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma , 2012 .

[27]  H. Rammensee,et al.  Toll‐like receptor‐dependent activation of several human blood cell types by protamine‐condensed mRNA , 2005, European journal of immunology.

[28]  M. Fotin‐Mleczek,et al.  Messenger RNA-based Vaccines With Dual Activity Induce Balanced TLR-7 Dependent Adaptive Immune Responses and Provide Antitumor Activity , 2011, Journal of immunotherapy.

[29]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[30]  Özlem Türeci,et al.  Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy , 2016, Nature.

[31]  S. Nair,et al.  RNA-Based Vaccines in Cancer Immunotherapy , 2015, Journal of immunology research.

[32]  G. Vanham,et al.  Type I Interferons Interfere with the Capacity of mRNA Lipoplex Vaccines to Elicit Cytolytic T Cell Responses. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[33]  C. Rudin,et al.  Poly(β-amino ester) Nanoparticle Delivery of TP53 Has Activity against Small Cell Lung Cancer In Vitro and In Vivo , 2013, Molecular Cancer Therapeutics.

[34]  H. Rammensee,et al.  Direct Injection of Protamine-protected mRNA: Results of a Phase 1/2 Vaccination Trial in Metastatic Melanoma Patients , 2009, Journal of immunotherapy.

[35]  T. Schumacher,et al.  Neoantigens in cancer immunotherapy , 2015, Science.

[36]  Ira Mellman,et al.  Cell biology of antigen processing in vitro and in vivo. , 2005, Annual review of immunology.

[37]  G. Linette,et al.  IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity. , 2013, The Journal of clinical investigation.

[38]  E. Mardis,et al.  A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells , 2015, Science.

[39]  N. Philpott,et al.  TNF-α-dependent maturation of local dendritic cells is critical for activating the adaptive immune response to virus infection , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[40]  John B. Shoven,et al.  I , Edinburgh Medical and Surgical Journal.

[41]  C. Heirman,et al.  Particle-mediated Intravenous Delivery of Antigen mRNA Results in Strong Antigen-specific T-cell Responses Despite the Induction of Type I Interferon , 2016, Molecular therapy. Nucleic acids.

[42]  Shizuo Akira,et al.  Innate Antiviral Responses by Means of TLR7-Mediated Recognition of Single-Stranded RNA , 2004, Science.

[43]  P. Kantoff,et al.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.

[44]  S. Akira,et al.  Species-Specific Recognition of Single-Stranded RNA via Toll-like Receptor 7 and 8 , 2004, Science.

[45]  U. Şahin,et al.  Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. , 2010, Cancer research.

[46]  K. Hahn,et al.  Amiloride inhibits macropinocytosis by lowering submembranous pH and preventing Rac1 and Cdc42 signaling , 2010, The Journal of cell biology.